West Pharmaceutical Services, Inc. (WST)
NYSE · Healthcare · Medical Instruments & Supplies
$376.76+3.23%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $26.5B
- P/E (trailing)
- 48.2
- Forward P/E
- 37.8
- Dividend yield
- 0.2%
- 52-week range
- $223.83 – $386.00
- 52-week change
- +37.23%
- EPS (trailing)
- $7.81
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 22, 2026
Fiscal year to Dec 2025
- Revenue
- $3.1B (+6.25%)
- Net income
- $494M
- Operating margin
- 19.0%
- Diluted EPS
- $6.79
- Free cash flow
- $469M
From the company’s annual report on SEC EDGAR.
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies.
Headquarters: Exton, United States · 10,800 employees · westpharma.com